Sempra (SRE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 7, might help the stock move higher if these key numbers are better than expectations. On ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Airbnb, Inc. driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 6, with a consensus EPS estimate of $0.93, reflecting an 8.1% year-over-year increase, and revenues projected at $3.03 billion, a 10.3% increase from the previous year [3][12]. - The consensus EPS estimate has been revised 0.33% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +3.78% for Airbnb, suggesting a likelihood of beating the consensus EPS estimate [12]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which increases the predictive power of the Earnings ESP [10]. Historical Performance - In the last reported quarter, Airbnb was expected to post earnings of $0.25 per share but delivered $0.24, resulting in a -4.00% surprise [13]. - Over the last four quarters, Airbnb has only beaten consensus EPS estimates once [14]. Conclusion - While Airbnb is positioned as a compelling earnings-beat candidate, other factors may influence stock movement beyond just earnings results [15][17].

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with the actual results having a significant impact on its near-term stock price [1][2]. Financial Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.03 per share, reflecting a year-over-year increase of 150% [3]. - Revenues are projected to be $148.85 million, which is a 36.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly reassessed their initial estimates [4]. - For BioCryst, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -66.67%, suggesting a bearish outlook from analysts [11]. Earnings Surprise History - In the last reported quarter, BioCryst was expected to post a loss of $0.07 per share but instead delivered break-even earnings, resulting in a surprise of +100.00% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - In the Zacks Medical - Drugs industry, Indivior PLC (INDV) is expected to report earnings of $0.26 per share for the same quarter, indicating a year-over-year decline of 40.9% [17]. - Indivior's revenue is projected to be $244.27 million, down 18.3% from the previous year, but it has an Earnings ESP of +11.54%, suggesting a likelihood of beating the consensus EPS estimate [18][19].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Castle Biosciences, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 4, with a consensus estimate of a quarterly loss of $0.51 per share, reflecting a year-over-year change of -264.5% [3]. - Revenues are projected to be $73.89 million, down 15.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 26% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [9][10]. - Castle Biosciences currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12][13]. Historical Performance - In the last reported quarter, Castle Biosciences was expected to post a loss of $0.08 per share but actually reported a loss of -$0.20, resulting in a surprise of -150.00% [14]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [15]. Industry Comparison - Moderna, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $2.99 per share, with revenues projected at $127.17 million, down 47.2% year-over-year [19][20]. - Moderna's consensus EPS estimate has been revised 1.4% lower, but it has a positive Earnings ESP of +7.22% and a Zacks Rank of 3, indicating a likelihood of beating the consensus estimate [20][21].